Leflunomide Mylan (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo synthesis of pyrimidine nucleotides. By limiting pyrimidine production, the drug suppresses the proliferation of activated T‑lymphocytes, thereby dampening the immune response that drives inflammation in rheumatoid and psoriatic arthritis.

The dosing regimen for Leflunomide Mylan is determined by the prescribing clinician based on the individual’s disease severity, prior therapy, and laboratory monitoring. Physicians typically start with a loading dose followed by a maintenance dose, but the exact schedule should be confirmed with the treating healthcare professional.

Leflunomide is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It is contraindicated during pregnancy and women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Leflunomide Mylan. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Leflunomide is often compared with methotrexate, another first‑line DMARD. While both reduce disease activity, leflunomide has a different safety profile, with less hepatic toxicity at low doses but a higher risk of hypertension and teratogenicity. Biologic agents such as TNF‑α inhibitors may be used when patients do not respond adequately to either leflunomide or methotrexate.

Leflunomide Mylan tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Leflunomide is taken orally as a tablet, usually with or without food according to the prescribing physician’s instructions. Swallow the tablet whole with a glass of water; do not crush or chew it unless directed otherwise.

The most serious adverse events include severe liver injury, which may present as jaundice or elevated liver enzymes, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Bone‑marrow suppression leading to anemia, leukopenia or thrombocytopenia, and teratogenic effects in pregnancy are also critical safety concerns that require regular monitoring.

Leflunomide is contraindicated in pregnant women, individuals with severe hepatic impairment, and patients with known hypersensitivity to the drug. Caution is also advised for those with uncontrolled hypertension, active infections, or significant bone‑marrow disorders. The prescriber should evaluate each patient’s medical history before initiating therapy.